Rapport Therapeutics Q2 FY26 net loss widens to $56.6 million; R&D expense more than doubled to $51.4 million

• Rapport Therapeutics posted a Q2 2026 net loss of $56.6 million, widening from $26.7 million a year earlier.
• R&D expense more than doubled to $51.4 million, driven by higher clinical-development and pipeline progression costs.
• SG&A rose 38.24% to $9.4 million on costs tied to business growth.
• Cash, cash equivalents and short-term investments fell to $436.1 million; runway projected into the second half of 2029.
• RAP-219 Phase 3 focal onset seizures program started, with FOCUS 1 and FOCUS 2 enrolling; bipolar mania Phase 2 topline data expected in October 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-333853), on August 05, 2026, and is solely responsible for the information contained therein.